TriSalus Life Sciences Inc

TLSI is in an early/fragile Stage 1 base after the mid-May flush; long-term downtrend remains intact but short-term EMAs have repaired and the Bullish Pivot Point signals structural repair. Price is oscillating in a tightening range above support but is extended above rising EMAs, so the medium-term bias is bullish while execution is best deferred. The strategy is to stalk pullbacks into the rising 9/21 EMA support zone in anticipation of a breakout.

• ↑2026 revenue guidance raised to $54–57 M, reflecting confidence in product rollout
• ↑Q1 2026 revenue $8.9 M with gross margin improving to 86% YoY
• ↓Q1 2026 revenue slipped 3% YoY to $8.9 M amid sales team transition